All Clinical Trials
Below is a list of all clinical trials, conducted by several of our specialty service lines. You may filter the list of trials by clicking the "Department" dropdown menu and selecting the area that you want to view or that pertains to you.
Clicking "Learn More" may either take you to more information about our departments that conduct the research, or to the official clinicaltrials.gov page for more information about the trial.
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (ZENITH)
Study # NCT07181109 Date Opened: 09/22/2025 Closing Date: 09/30/2030 Principal Investigator: Paul Gurbel, M.D. Sponsor: Alnylam Pharmaceuticals • Status: Recruiting
A Phase III trial to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a): ACCLAIM-Lp(a)
Study # NCT06292013 Date Opened: 03/25/2024 Closing Date: 12/31/2029 Principal Investigator: Paul Gurbel, M.D. Sponsor: Eli Lilly and Company • Status: Active, not recruiting
A single arm, multicenter, open-label extension (OLE) trial to evaluate long- term safety and tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial
Study # NCT05900141 Date Opened: 09/29/2023 Closing Date: 08/24/2028 Principal Investigator: Paul Gurbel, M.D. Sponsor: Novartis Pharmaceuticals • Status: Active, not recruiting
A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label pelacarsen in participants with elevated Lp(a) and established ASCVD
Study # NCT06875973 Date Opened: 05/19/2025 Closing Date: 12/08/2030 Principal Investigator: Paul Gurbel, M.D. Sponsor: Novartis Pharmaceuticals • Status: Active, not recruiting
A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)
Study # VICTORION-2 PREVENT Sponsor: Novartis Pharmaceuticals • Status: Active, not recruiting
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants with Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
Study # NCT06948435 Date Opened: 04/30/2025 Principal Investigator: Paul Gurbel, M.D. Sponsor: Eli Lilly and Company • Status: Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Study # NCT06383390 Principal Investigator: Paul Gurbel, M.D. Sponsor: Eli Lilly and Company • Status: Active, not recruiting
